Beat · Professional+ access
Biotech & Pharma
Drug pipelines, clinical-stage therapeutics, and pharma programs targeting diseases that disproportionately or exclusively affect women.
Full Biotech & Pharma access during your trial. Already a member? See plans.
What you'll get inside
Biotech & Pharma sub-beats
Endometriosis therapeutics
Non-hormonal, non-opioid pipelines — the biggest unmet need in women's health pharma.
Non-hormonal contraception
YourChoice, Dare and others — first new MOA approval would be landmark.
Gynecological oncology
ADCs and next-generation ovarian and cervical cancer therapeutics.
Fertility biotech
Precision fertility, IVG, oocyte engineering, Gameto and Celmatix lineage.
PCOS therapeutics
Clinical-stage MOA candidates beyond off-label hormonal therapy.
Included with Professional
- Every Biotech & Pharma signal — funding, research, policy, launches
- OVUM analyst commentary on each signal
- Sub-beat market maps and lifecycle views
- Founder and organization profiles
- Daily and weekly digests in your inbox
- Full ecosystem and company directory